AZD5305 in Patients with BRCAm localized high-risk prostate cancer

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localized High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localized High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy

For More Information:

https://clinicaltrials.gov/study/NCT06952803?term=Adjuvant%20Saruparib%20(AZD5305)%20in%20Patients%20with%20BRCAm&viewType=Card&rank=1